| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| Other Sizes |
| Targets |
2-Oxo clopidogrel hydrochloride does not have intrinsic pharmacological activity but is a key intermediate metabolite in the bioactivation of clopidogrel. Clopidogrel is a prodrug that requires hepatic metabolism to generate the active thiol metabolite, which irreversibly inhibits the P2Y12 ADP receptor on platelets. 2-Oxo clopidogrel is formed during the first oxidation step of clopidogrel metabolism and is a precursor to the active metabolite.
|
|---|---|
| ln Vitro |
In vitro, 2-oxo clopidogrel hydrochloride is used as a reference standard for analytical method development and validation. It is not pharmacologically active itself but is important for studying clopidogrel metabolism and pharmacokinetics. The compound is used in in vitro metabolism studies to characterize the enzymes involved in clopidogrel bioactivation, particularly CYP450 isoforms such as CYP2C19 and CYP3A4.
|
| ln Vivo |
In vivo, 2-oxo clopidogrel is formed as an intermediate during the hepatic metabolism of clopidogrel. It is further metabolized to the active thiol metabolite that irreversibly inhibits P2Y12 ADP receptors on platelets. The compound is used in pharmacokinetic studies to measure clopidogrel metabolism and to identify patients with poor metabolism due to genetic polymorphisms in CYP2C19.
|
| Enzyme Assay |
The in vitro enzyme/receptor binding assay for 2-oxo clopidogrel hydrochloride is not typically performed as it is not an active drug. However, metabolism studies using liver microsomes or recombinant CYP450 enzymes are conducted to characterize the conversion of clopidogrel to 2-oxo clopidogrel and subsequently to the active metabolite. These assays measure the formation of 2-oxo clopidogrel by HPLC-MS/MS and determine the kinetic parameters (Km, Vmax) of the metabolic reactions.
|
| Cell Assay |
In vitro cellular studies with 2-oxo clopidogrel hydrochloride are limited as it is not an active compound. However, platelet aggregation assays are performed using the active metabolite generated from clopidogrel metabolism, with 2-oxo clopidogrel as a reference standard for analytical purposes. Hepatocyte cultures or liver microsomes are used to study the metabolic conversion of clopidogrel to 2-oxo clopidogrel and its subsequent metabolism.
|
| Animal Protocol |
In vivo animal experiments with 2-oxo clopidogrel hydrochloride are not typically performed as it is a metabolite rather than an active drug. However, pharmacokinetic studies in animals and humans measure plasma concentrations of 2-oxo clopidogrel as a marker of clopidogrel metabolism. These studies evaluate the effects of genetic polymorphisms, drug interactions, and other factors on clopidogrel bioactivation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2-oxo clopidogrel hydrochloride include solubility in DMSO and methanol. The compound has a molecular weight of 374.28 g/mol, melting point of 133-135°C, and appears as a pale yellow to pale brown solid. It has the SMILES COC(=O)C(C1=CC=CC=C1Cl)N2CCC3C(=CC(=O)S3)C2.Cl. Storage at -20°C for powder is recommended.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2-oxo clopidogrel hydrochloride are derived from its use as a metabolite of clopidogrel. As a research standard, it is not intended for human therapeutic use. The compound should be handled with standard laboratory safety precautions. No significant toxicity has been reported for the metabolite itself, but clopidogrel has well-characterized safety profiles including bleeding risk.
|
| Additional Infomation |
2-Oxo clopidogrel hydrochloride is also known as methyl 2-(2-chlorophenyl)-2-(2-oxo-4,6,7,7a-tetrahydrothieno[3,2-c]pyridin-5-yl)acetate;hydrochloride. It is an essential intermediate metabolite from which the active metabolite of clopidogrel is formed. The compound is used as a reference standard in pharmaceutical research for analytical method development, quality control, and metabolism studies. It is supplied as a powder with ≥98% purity.
|
| Molecular Formula |
C16H16NO3SCL.HCL
|
|---|---|
| Molecular Weight |
374.28208
|
| Exact Mass |
373.03
|
| CAS # |
1219432-42-4
|
| PubChem CID |
46782651
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
23
|
| Complexity |
496
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC(=O)C(C1=CC=CC=C1Cl)N2CCC3C(=CC(=O)S3)C2.Cl
|
| InChi Key |
KCFLQPXPVKZERK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H16ClNO3S.ClH/c1-21-16(20)15(11-4-2-3-5-12(11)17)18-7-6-13-10(9-18)8-14(19)22-13;/h2-5,8,13,15H,6-7,9H2,1H3;1H
|
| Chemical Name |
methyl 2-(2-chlorophenyl)-2-(2-oxo-4,6,7,7a-tetrahydrothieno[3,2-c]pyridin-5-yl)acetate;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6718 mL | 13.3590 mL | 26.7180 mL | |
| 5 mM | 0.5344 mL | 2.6718 mL | 5.3436 mL | |
| 10 mM | 0.2672 mL | 1.3359 mL | 2.6718 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
